Table 2.

HBV entry inhibitors. Based on table from Ref. [106] and subsequently updated.

Class	Substance	Target	Status	References
Attachment inhibitors	Heparin	S, M, L	FDA-approved	[51]
	Suramin	S, M, L	FDA-approved	[103]
	Proanthocyanidin	PreS1	Preclinical	[107]
	SALP	HSPGs	Preclinical	[101]
NTCP substrate inhibitors	Taurocholic acid, UDCA, TUDCA, GUDCA	NTCP	/	[108,109,110]
	Ezetimib	NTCP/NPC1L1	FDA-approved	[111]
	Irbesartan	NTCP	FDA-approved	[112]
NTCP inhibitors	Myrcludex B	NTCP/Interferes slightly with bile acid uptake	Phase III	[113,114]
	CsA	NTCP/Interferes strongly with bile acid uptake	FDA-approved	[93]
	SCY450	NTCP/No interference with bile acid uptake	Preclinical	[115]
	SCY995	NTCP/No interference with bile acid uptake	Preclinical	[115]
	Vanitaracin A	NTCP/Interferes strongly with bile acid uptake	Preclinical	[116]
	Ro41-5253	NTCP/Antagonist of retinoic acid receptor which regulates NTCP expression	Preclinical	[117]
	Evans blue	NTCP	FDA-approved	[118]